Implications for surveillance for breast cancer patients based on the internally and externally validated BRENDA-metastatic recurrence score.
Florian K EbnerJessica SalmenDavut DayanMatthias KieselRegine WoltersWolfgang JanniAchim WöckelManfred WischnewskyPublished in: Breast cancer research and treatment (2023)
The evaluation showed that the BRENDA-Score is a robust predictive tool for breast cancer recurrence and site of metastases in the first five years after diagnosis. It outperforms intrinsic subtypes and the Nottingham prognostic score. The BRENDA-score could be a tool for a risk orientated and targeted follow up.